Emery-Dreifuss muscular dystrophy is defined by a clinical triad: joint contractures that appear early, muscle weakness and wasting in a distinctive distribution, and cardiac disease. The heart involvement is what separates it from most other muscular dystrophies in terms of urgency.
Key takeaways
- The triad is contractures, weakness and cardiac disease. GeneReviews describes contractures of the elbows, ankles and posterior neck appearing in the first two decades, usually before significant weakness.
- Weakness follows a humeroperoneal pattern, meaning the upper arm and the outer lower leg first, before it extends to the shoulder girdle, pelvic girdle and trunk.
- Cardiac involvement typically appears from the end of the second decade onward and can include conduction block and arrhythmia. GeneReviews notes that sudden cardiac death can be the first manifestation, which is why cardiac surveillance is the centre of management.
- Inheritance can be X-linked (EMD, FHL1), autosomal dominant (LMNA and others) or rarely autosomal recessive. Female heterozygotes for an EMD variant are usually asymptomatic but carry cardiac risk of their own.
- There is no dedicated ICD-10-CM code. It sits under G71.09, other specified muscular dystrophies, where it appears by name in the inclusion terms.
What Emery-Dreifuss muscular dystrophy is
GeneReviews characterises the condition by the clinical triad of joint contractures, muscle weakness and wasting, and cardiac disease, with respiratory function impaired in some people. Age of onset, severity and rate of progression vary both between families and within the same family, ranging from an early and severe childhood presentation to a late-onset, slowly progressive adult one. Onset after age 20 is described as exceedingly rare.
That variability is worth holding onto if you have just received a diagnosis, because it means the course described in one family's account may bear little resemblance to another's. What does not vary is the need to take the cardiac side seriously.
The contractures usually come first
Contractures are the shortening of muscle and tendon that pulls a joint into a fixed position. In this condition they begin in early childhood and are often the first thing anyone notices, sometimes years before weakness is obvious.
The characteristic pattern is elbows, ankles and the posterior cervical muscles. Neck involvement limits how far the head can be flexed forward and later restricts movement of the whole spine, which is why a rigid spine is part of the clinical picture. Contractures may extend to the fingers and wrists. Their degree and progression are variable and not reliably tied to age. When severe, they can themselves cost someone the ability to walk by limiting spine and lower limb movement, independently of how strong the muscles are.
The weakness pattern is humeroperoneal
The distribution has a name because it is unusual. Humeroperoneal means the muscles of the upper arm, biceps and triceps, and the peroneal compartment of the lower leg along with tibialis anterior. Weakness is bilateral and roughly symmetric, and later extends to the scapular muscles, the pelvic girdle and the axial muscles of the trunk.
GeneReviews describes the progression as usually slow through the first three decades of life, becoming more rapid afterward. Electromyography typically shows myopathic features with normal nerve conduction, and muscle MRI or CT shows fatty infiltration concentrated in the paravertebral, gluteal, quadriceps, biceps, hamstring, adductor, soleus and gastrocnemius muscles.
The heart is what changes management
This is the part of the article that matters most.
Cardiac involvement usually appears from the end of the second decade into the third. Symptoms can include palpitations, presyncope, syncope and poor exercise tolerance, but GeneReviews is explicit that sudden cardiac death can occur as the first event in some individuals. Conduction defects reported include sinus bradycardia, sinoatrial block, atrial standstill, first-degree atrioventricular block, bundle branch block and complete heart block requiring a pacemaker or an implantable cardioverter-defibrillator. Atrial and ventricular arrhythmias are frequent, and affected individuals are at risk of cerebral emboli. Congestive heart failure, dilated or hypertrophic cardiomyopathy, and end-stage heart failure leading to transplantation are all reported.
The published surveillance recommendation in GeneReviews is ECG, Holter monitoring and echocardiography at least annually, with additional cardiac assessment as needed, plus pulmonary function testing every two to three years and annually where there is respiratory compromise. What that means in practice for any individual is a matter for the treating cardiologist and neuromuscular team, ideally ones who have seen this condition before. The point for a family reading this page is simply that cardiac follow-up is not optional and does not wait for symptoms.
Genes and inheritance
Several genes produce the same clinical picture, and which one is involved determines what the family needs to know.
| Gene | Inheritance | Note |
|---|---|---|
| EMD (emerin) | X-linked | The originally described form |
| FHL1 | X-linked | Can involve more prominent respiratory dysfunction |
| LMNA (lamin A/C) | Autosomal dominant | 65% of cases arise from a de novo variant |
| SUN2, SYNE1, SYNE2, TMEM43 | Autosomal dominant | Less common |
| LMNA, SUN1 | Autosomal recessive | Rare, few reported cases |
Two points from GeneReviews deserve emphasis. First, in the X-linked forms, female heterozygotes are usually asymptomatic but are at risk of developing cardiac disease, usually after age 50, and rarely a progressive muscular dystrophy. A carrier is not simply a carrier here. Second, in the autosomal dominant LMNA form, 65% of affected individuals have a de novo variant, so an absent family history does not argue against the diagnosis.
Both facts are reasons this is a condition where genetic counselling has practical consequences, for testing at-risk relatives and for reproductive planning. Once the family variant is identified, prenatal and preimplantation genetic testing become possible.
Emery-Dreifuss muscular dystrophy ICD-10: there is no dedicated code
This is a common source of confusion, and the answer is clean.
ICD-10-CM has specific codes for several muscular dystrophies but not for this one. It is classified under G71.09, other specified muscular dystrophies, and it appears there explicitly: the inclusion terms published for G71.09 list "benign scapuloperoneal muscular dystrophy with early contractures [Emery-Dreifuss]". So G71.09 is not a fallback or a best guess. It is where the classification puts this condition by name.
| Code | Descriptor |
|---|---|
| G71.0 | Muscular dystrophy. Parent category, not billable on its own |
| G71.01 | Duchenne or Becker muscular dystrophy |
| G71.02 | Facioscapulohumeral muscular dystrophy |
| G71.03 | Limb girdle muscular dystrophies |
| G71.09 | Other specified muscular dystrophies, including Emery-Dreifuss |
Because the code does not carry the cardiac picture, the conduction defect, arrhythmia, cardiomyopathy or device dependence is documented and coded separately as clinically appropriate. Our muscular dystrophy ICD-10 reference covers the wider category, and the limb girdle page covers the subdivided G71.03 codes.
Cautions the sources flag
GeneReviews lists agents and circumstances to avoid, and two are worth knowing before an emergency makes them relevant. Triggers for malignant hyperthermia, specifically depolarising muscle relaxants such as succinylcholine and volatile anaesthetics such as halothane and isoflurane, are listed as agents to avoid. Obesity is also listed. Anyone facing planned surgery should make sure the anaesthetic team knows the diagnosis well in advance.
Where myostatin research sits
This site covers myostatin, the protein that restrains muscle growth, so it is worth saying plainly where that field stands in relation to this condition.
Myostatin inhibition has been tested extensively in muscular dystrophy, most heavily in Duchenne, and has repeatedly produced biological signals without functional benefit. We have gone through the programmes one by one in myostatin inhibitors in Duchenne; ACE-031 was stopped after safety signals and apitegromab was developed for spinal muscular atrophy. None of it applies to Emery-Dreifuss muscular dystrophy, and there is a structural reason beyond the trial record: the threat here is largely cardiac, and a drug that adds skeletal muscle bulk does not address a conduction system problem. Supplements marketed as myostatin inhibitors, reviewed in myostatin inhibitor supplements, have no relevance at all.
Sources
- GeneReviews: Emery-Dreifuss muscular dystrophy
- MedlinePlus Genetics: Emery-Dreifuss muscular dystrophy
- Muscular Dystrophy Association: Emery-Dreifuss muscular dystrophy
- AAPC ICD-10-CM code G71.09
Frequently asked questions
What is the ICD-10 code for Emery-Dreifuss muscular dystrophy?
G71.09, other specified muscular dystrophies. There is no dedicated code, but this is not an approximation: the inclusion terms published under G71.09 name benign scapuloperoneal muscular dystrophy with early contractures, Emery-Dreifuss, directly. The parent category G71.0 is not billable on its own.
Why is the heart involved in a muscle disease?
The proteins affected, emerin and lamin A/C among them, sit in the nuclear envelope of cells rather than in the contractile machinery alone, and cardiac tissue depends on them too. The clinical consequence is that the conduction system and the heart muscle can both be affected, which is why GeneReviews recommends ECG, Holter monitoring and echocardiography at least annually.
Can female carriers be affected?
In the X-linked forms, female heterozygotes are usually asymptomatic, but GeneReviews notes they are at risk of developing cardiac disease, usually after age 50, rarely a progressive muscular dystrophy and very rarely the full phenotype. That is a reason for carrier relatives to have their own cardiac assessment discussed with a clinician rather than assuming carrier status is inconsequential.
Does a negative family history rule it out?
No. In the autosomal dominant form caused by LMNA variants, GeneReviews reports that 65% of affected individuals have a de novo variant, meaning the change arose new in that person. A family with no previous history can still have an affected child.
How is it different from limb girdle muscular dystrophy?
The distribution and the sequence differ. Emery-Dreifuss typically starts with contractures and weakness in the upper arms and lower legs, while the limb girdle group starts with proximal weakness around the shoulders and hips. Cardiac conduction disease is a defining feature of Emery-Dreifuss rather than a subtype-dependent risk. They also code differently, at G71.09 and G71.03.
This article is for educational purposes only and is not medical advice. It summarises what published clinical sources describe about Emery-Dreifuss muscular dystrophy and does not recommend or discourage any treatment, test or monitoring schedule. Diagnosis, cardiac surveillance, anaesthetic planning and genetic testing decisions belong with a qualified neuromuscular specialist, cardiologist and genetic counsellor.